InterVenn Biosciences, a company developing an AI-imbued platform for diagnostic cancer test design, raised $34 million.
View Article on VentureBeat
AI,Big Data,Business,Cloud,Dev,Enterprise,Entrepreneur,ai,artificial intelligence,category-/Health/Health Conditions/Cancer,category-/Health/Health Foundations & Medical Research,funding daily,health care,Intervenn,Intervenn Biosciences
funding daily